vs
American Assets Trust, Inc.（AAT）与Orthofix Medical Inc.（OFIX）财务数据对比。点击上方公司名可切换其他公司
Orthofix Medical Inc.的季度营收约是American Assets Trust, Inc.的2.0倍（$219.9M vs $110.6M），American Assets Trust, Inc.净利率更高（6.1% vs -1.0%，领先7.1%），Orthofix Medical Inc.同比增速更快（2.0% vs 1.8%），过去两年Orthofix Medical Inc.的营收复合增速更高（8.0% vs -0.1%）
该公司是一家大型英国投资信托，在伦敦证券交易所上市，同时是富时250指数的成分股，现任董事长为获颁CBE勋章的伊恩·弗格森。
Orthofix医疗是全球知名骨科医疗器械企业，专注于研发、生产及销售脊柱植入物、骨科创伤产品、骨生长刺激治疗设备及再生医疗产品，服务全球多地的骨科医师与医疗机构，致力于提升肌肉骨骼疾病患者的诊疗效果。
AAT vs OFIX — 直观对比
营收规模更大
OFIX
是对方的2.0倍
$110.6M
营收增速更快
OFIX
高出0.1%
1.8%
净利率更高
AAT
高出7.1%
-1.0%
两年增速更快
OFIX
近两年复合增速
-0.1%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $110.6M | $219.9M |
| 净利润 | $6.7M | $-2.2M |
| 毛利率 | — | 71.1% |
| 营业利润率 | 23.4% | 0.2% |
| 净利率 | 6.1% | -1.0% |
| 营收同比 | 1.8% | 2.0% |
| 净利润同比 | -16.3% | 92.4% |
| 每股收益（稀释后） | $0.08 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AATOFIX
| Q1 26 | $110.6M | — | ||
| Q4 25 | $110.1M | $219.9M | ||
| Q3 25 | $109.6M | $205.6M | ||
| Q2 25 | $107.9M | $203.1M | ||
| Q1 25 | $108.6M | $193.6M | ||
| Q4 24 | $113.5M | $215.7M | ||
| Q3 24 | $122.8M | $196.6M | ||
| Q2 24 | $110.9M | $198.6M |
净利润AATOFIX
| Q1 26 | $6.7M | — | ||
| Q4 25 | — | $-2.2M | ||
| Q3 25 | $4.5M | $-22.8M | ||
| Q2 25 | $5.5M | $-14.1M | ||
| Q1 25 | $42.5M | $-53.1M | ||
| Q4 24 | — | $-29.1M | ||
| Q3 24 | $16.7M | $-27.4M | ||
| Q2 24 | $11.9M | $-33.4M |
毛利率AATOFIX
| Q1 26 | — | — | ||
| Q4 25 | 59.4% | 71.1% | ||
| Q3 25 | 60.5% | 72.2% | ||
| Q2 25 | 62.6% | 68.7% | ||
| Q1 25 | 62.0% | 62.8% | ||
| Q4 24 | 61.3% | 69.0% | ||
| Q3 24 | 65.5% | 68.7% | ||
| Q2 24 | 63.6% | 67.8% |
营业利润率AATOFIX
| Q1 26 | 23.4% | — | ||
| Q4 25 | 21.1% | 0.2% | ||
| Q3 25 | 22.6% | -8.3% | ||
| Q2 25 | 24.1% | -7.9% | ||
| Q1 25 | 66.3% | -25.2% | ||
| Q4 24 | 26.5% | -5.3% | ||
| Q3 24 | 30.8% | -9.6% | ||
| Q2 24 | 27.8% | -12.5% |
净利率AATOFIX
| Q1 26 | 6.1% | — | ||
| Q4 25 | — | -1.0% | ||
| Q3 25 | 4.1% | -11.1% | ||
| Q2 25 | 5.1% | -6.9% | ||
| Q1 25 | 39.2% | -27.4% | ||
| Q4 24 | — | -13.5% | ||
| Q3 24 | 13.6% | -13.9% | ||
| Q2 24 | 10.7% | -16.8% |
每股收益（稀释后）AATOFIX
| Q1 26 | $0.08 | — | ||
| Q4 25 | $0.06 | $-0.05 | ||
| Q3 25 | $0.07 | $-0.57 | ||
| Q2 25 | $0.09 | $-0.36 | ||
| Q1 25 | $0.70 | $-1.35 | ||
| Q4 24 | $0.14 | $-0.76 | ||
| Q3 24 | $0.28 | $-0.71 | ||
| Q2 24 | $0.20 | $-0.88 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $118.3M | $82.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $1.1B | $450.0M |
| 总资产 | $2.9B | $850.6M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资AATOFIX
| Q1 26 | $118.3M | — | ||
| Q4 25 | $129.4M | $82.0M | ||
| Q3 25 | $138.7M | $62.9M | ||
| Q2 25 | $143.7M | $65.6M | ||
| Q1 25 | $143.9M | $58.0M | ||
| Q4 24 | $425.7M | $83.2M | ||
| Q3 24 | $533.0M | $30.1M | ||
| Q2 24 | $114.9M | $26.4M |
总债务AATOFIX
| Q1 26 | — | — | ||
| Q4 25 | $1.7B | — | ||
| Q3 25 | — | $157.2M | ||
| Q2 25 | — | $157.0M | ||
| Q1 25 | — | $156.9M | ||
| Q4 24 | $2.0B | $157.0M | ||
| Q3 24 | — | $118.5M | ||
| Q2 24 | — | $118.0M |
股东权益AATOFIX
| Q1 26 | $1.1B | — | ||
| Q4 25 | $1.2B | $450.0M | ||
| Q3 25 | $1.2B | $442.5M | ||
| Q2 25 | $1.2B | $458.3M | ||
| Q1 25 | $1.2B | $458.3M | ||
| Q4 24 | $1.2B | $503.1M | ||
| Q3 24 | $1.2B | $525.9M | ||
| Q2 24 | $1.2B | $546.0M |
总资产AATOFIX
| Q1 26 | $2.9B | — | ||
| Q4 25 | $2.9B | $850.6M | ||
| Q3 25 | $2.9B | $832.6M | ||
| Q2 25 | $3.0B | $837.2M | ||
| Q1 25 | $3.0B | $823.1M | ||
| Q4 24 | $3.3B | $893.3M | ||
| Q3 24 | $3.4B | $867.9M | ||
| Q2 24 | $3.0B | $882.0M |
负债/权益比AATOFIX
| Q1 26 | — | — | ||
| Q4 25 | 1.48× | — | ||
| Q3 25 | — | 0.36× | ||
| Q2 25 | — | 0.34× | ||
| Q1 25 | — | 0.34× | ||
| Q4 24 | 1.72× | 0.31× | ||
| Q3 24 | — | 0.23× | ||
| Q2 24 | — | 0.22× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $27.7M |
| 自由现金流经营现金流 - 资本支出 | — | $16.8M |
| 自由现金流率自由现金流/营收 | — | 7.6% |
| 资本支出强度资本支出/营收 | 14.5% | 4.9% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-1.3M |
8季度趋势，按日历期对齐
经营现金流AATOFIX
| Q1 26 | — | — | ||
| Q4 25 | $167.1M | $27.7M | ||
| Q3 25 | $40.5M | $12.4M | ||
| Q2 25 | $49.2M | $11.6M | ||
| Q1 25 | $36.9M | $-18.4M | ||
| Q4 24 | $207.1M | $23.7M | ||
| Q3 24 | $52.4M | $11.7M | ||
| Q2 24 | $59.3M | $9.0M |
自由现金流AATOFIX
| Q1 26 | — | — | ||
| Q4 25 | $94.9M | $16.8M | ||
| Q3 25 | $23.1M | $2.5M | ||
| Q2 25 | $28.4M | $4.5M | ||
| Q1 25 | $20.4M | $-25.1M | ||
| Q4 24 | $136.9M | $15.2M | ||
| Q3 24 | $28.0M | $6.3M | ||
| Q2 24 | $43.6M | $-360.0K |
自由现金流率AATOFIX
| Q1 26 | — | — | ||
| Q4 25 | 86.2% | 7.6% | ||
| Q3 25 | 21.1% | 1.2% | ||
| Q2 25 | 26.3% | 2.2% | ||
| Q1 25 | 18.8% | -13.0% | ||
| Q4 24 | 120.7% | 7.0% | ||
| Q3 24 | 22.8% | 3.2% | ||
| Q2 24 | 39.3% | -0.2% |
资本支出强度AATOFIX
| Q1 26 | 14.5% | — | ||
| Q4 25 | 65.6% | 4.9% | ||
| Q3 25 | 15.9% | 4.8% | ||
| Q2 25 | 19.3% | 3.5% | ||
| Q1 25 | 15.1% | 3.5% | ||
| Q4 24 | 61.9% | 4.0% | ||
| Q3 24 | 19.9% | 2.7% | ||
| Q2 24 | 14.1% | 4.7% |
现金转化率AATOFIX
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 8.98× | — | ||
| Q2 25 | 9.01× | — | ||
| Q1 25 | 0.87× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 3.15× | — | ||
| Q2 24 | 4.98× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AAT
| Rental income | $104.4M | 94% |
| Other | $6.2M | 6% |
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
